Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer

Molecular Cancer, Journal Year: 2023, Volume and Issue: 22(1)

Published: July 6, 2023

Abstract Breast cancer is the second leading cause of death for women worldwide. The heterogeneity this disease presents a big challenge in its therapeutic management. However, recent advances molecular biology and immunology enable to develop highly targeted therapies many forms breast cancer. primary objective therapy inhibit specific target/molecule that supports tumor progression. Ak strain transforming, cyclin-dependent kinases, poly (ADP-ribose) polymerase, different growth factors have emerged as potential targets subtypes. Many drugs are currently undergoing clinical trials, some already received FDA approval monotherapy or combination with other treatment yet achieve promise against triple-negative (TNBC). In aspect, immune has come up promising approach specifically TNBC patients. Different immunotherapeutic modalities including immune-checkpoint blockade, vaccination, adoptive cell transfer been extensively studied setting cancer, especially approved blockers chemotherapeutic treat several trials ongoing. This review provides an overview developments advancements immunotherapies treatment. successes, challenges, prospects were critically discussed portray their profound prospects.

Language: Английский

---

Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer

Frontiers in Oncology, Journal Year: 2022, Volume and Issue: 12

Published: June 20, 2022

Breast cancer is the most commonly diagnosed (estimated 2.3 million new cases in 2020) and leading cause of death 685,000 deaths women globally. cancers have been categorized into four major molecular subtypes based on immunohistochemistry (IHC) expression classic hormone growth factor receptors including estrogen receptor (ER), progesterone (PR), human epidermal 2 (HER2), as well a proliferation marker Ki-67 protein expression. Triple-negative breast (TNBC), subtype lacking ER, PR, HER2 expression, associated with high metastatic potential poor prognosis. TNBC accounts for approximately only 15%-20% diagnoses; it responsible cancer-related due to lack targeted treatment options this patient population, currently, systemic chemotherapy, radiation, surgical excision remain modalities these patients TNBC. Although general do not robust response immunotherapy, subset has demonstrated tumor mutation burden tumor-infiltrating lymphocytes, resembling features observed melanoma or lung cancers, which can benefit from immune checkpoint inhibitors (ICIs). Therefore, immunogenic nature aggressive disease presented an opportunity development TNBC-targeting immunotherapies. The recent US Food Drug Administration approval atezolizumab combination chemotherapeutic agent nab-paclitaxel PD-L1-positive unresectable, locally advanced, led era immunotherapy treatment. In addition, becomes active research area, both biology field oncology field. review, we will extend our coverage discoveries preclinical early results clinical trials molecule-based therapy cytokines, monoclonal antibodies, antibody-drug conjugates, bi-specific tri-specific ICIs, neoantigen vaccines; oncolytic virus-based therapies adoptive cell transfer-based TIL, chimeric antigen receptor-T (CAR-T), CAR-NK, CAR-M, T-cell receptor-T. end, list series challenges opportunities prospectively reveal novel technologies such high-throughput single-cell sequencing CRISPR gene editing-based screening generate knowledges immunotherapy.

Language: Английский

---

Emerging Targeted Therapies for HER2-Positive Breast Cancer

Cancers, Journal Year: 2023, Volume and Issue: 15(7), P. 1987 - 1987

Published: March 26, 2023

Breast cancer is the most common in women and leading cause of death. HER2 overexpression found approximately 20% breast cancers associated with a poor prognosis shorter overall survival. Tratuzumab, monoclonal antibody directed against receptor, standard care treatment. However, third patients do not respond to therapy. Given high rate resistance, other HER2-targeted strategies have been developed, including antibodies such as pertuzumab margetuximab, trastuzumab-based drug conjugates trastuzumab-emtansine (T-DM1) trastuzumab-deruxtecan (T-DXd), tyrosine kinase inhibitors like lapatinib tucatinib, among others. Moreover, T-DXd has proven be use HER2-low subtype, which suggests that therapies could successful this recently defined new subclassification. When progress multiple strategies, there are several available; however, treatment options limited, potential combination drugs, immune checkpoint inhibitors, CAR-T cells, CAR-NK, CAR-M, vaccines an interesting appealing field still development. In review, we will discuss highlights pitfalls different combinations overcome metastatic disease resistance

Language: Английский

---

Glutathione-Exhausting Nanoprobes for NIR-II Fluorescence Imaging-Guided Surgery and Boosting Radiation Therapy Efficacy via Ferroptosis in Breast Cancer

ACS Nano, Journal Year: 2023, Volume and Issue: 17(12), P. 11345 - 11361

Published: June 5, 2023

Breast-conserving surgery (BCS) is the standard of care for early breast cancer patients, while high ratio reoperation still a challenge due to inaccurate margin assessments. In patients with locally advanced or cancer, radiotherapy an important treatment local control improvement quality life. However, enhancing sensitization unmet medical need. To solve above clinical predicaments, glutathione (GSH) exhausting virus-like silicon dioxide nanoprobe Gd coating and folic acid (FA) modification designed. After loading ICG in mesopores, VGd@ICG-FA probe efficiently targets tumor cells resolution, its morphology folate anchoring. Especially, fabricated enables identification tiny cancers navigates precise under NIR-II fluorescence imaging. Moreover, after nanoprobes enter into cytoplasm cells, tetrasulfide linkages silica framework are broken triggering GSH concentrations. turn, exhausts disrupt intracellular reactive oxygen species (ROS) homeostasis, produces more ROS radiotherapy, further activating ferroptosis, resulting enhancement cancer. Therefore, our exhibits tremendous potential as imaging agent no systematic side effects nanotherapeutics boosting radiation sensitivity future translation

Language: Английский

---

Cancer Vaccines for Triple-Negative Breast Cancer: A Systematic Review

Vaccines, Journal Year: 2023, Volume and Issue: 11(1), P. 146 - 146

Published: Jan. 9, 2023

Triple-negative breast cancer (TNBC) is the subtype of with poorest outcomes, and associated a high risk relapse metastasis. The treatment choices for this malignancy have been confined to conventional chemotherapeutic agents, due lack expression canonical molecular targets. Immunotherapy has recently changing paradigm many types tumors, approach evoking active immune responses in milieu tumors through vaccines introduced as one most novel immunotherapeutic approaches. Accordingly, number or prevention recurrence developed are currently being studied TNBC patients, while none yet received any approvals. To elucidate efficacy safety these vaccines, we performed systematic review available literature on topic. After searching PubMed, Scopus, Web Science, Embase, Cochrane CENTRAL, Google Scholar databases, total 5701 results were obtained, from which 42 clinical studies eventually included based predefined criteria. overall quality was acceptable. However, reporting outcomes survival progression some (which presented conference abstracts) well heterogeneity reported study designs, not able carry out meta-analysis. A 32 different so far evaluated majority belonging peptide-based vaccine type. other cell nucleic acid (RNA/DNA)-based categories. Most proved be safe low-grade, local adverse events could efficiently evoke cellular responses; however, trials demonstrate significant improvements indices efficacy. This part limited randomized studies, population each trial. encouraging published trials, anticipate that strategy show its potential larger, phase III near future.

Language: Английский

---

The anti-cancer immune response in breast cancer: current and emerging biomarkers and treatments

Trends in cancer, Journal Year: 2024, Volume and Issue: 10(6), P. 490 - 506

Published: March 22, 2024

Language: Английский

---

Molecular and functional insight into anti-EGFR nanobody: Theranostic implications for malignancies

Life Sciences, Journal Year: 2024, Volume and Issue: 345, P. 122593 - 122593

Published: March 28, 2024

Language: Английский

---

Insights into therapeutic peptides in the cancer-immunity cycle: Update and challenges

Acta Pharmaceutica Sinica B, Journal Year: 2024, Volume and Issue: 14(9), P. 3818 - 3833

Published: May 13, 2024

Immunotherapies hold immense potential for achieving durable potency and long-term survival opportunities in cancer therapy. As vital biological mediators, peptides with high tissue penetration superior selectivity offer significant promise enhancing immunotherapies (CITs). However, physicochemical peptide features such as conformation stability pose challenges to their on-target efficacy. This review provides a comprehensive overview of recent advancements therapeutic targeting key steps the cancer-immunity cycle (CIC), including tumor antigen presentation, immune cell regulation, checkpoint signaling. Particular attention is given associated these boosting CIC within context clinical progress. Furthermore, possible future developments this field are also discussed provide insights into emerging CITs robust efficacy safety profiles.

Language: Английский

---

Exploring innovative strategies for identifying anti-breast cancer compounds by integrating 2D/3D-QSAR, molecular docking analyses, ADMET predictions, molecular dynamics simulations, and MM-PBSA approaches

Journal of Molecular Structure, Journal Year: 2024, Volume and Issue: 1320, P. 139500 - 139500

Published: July 31, 2024

Language: Английский

---

Signaling pathway dysregulation in breast cancer

Oncotarget, Journal Year: 2025, Volume and Issue: 16(1), P. 168 - 201

Published: March 13, 2025

// Dinara Ryspayeva 1 , 2 3 4 Attila A. Seyhan 5 William J. MacDonald Connor Purcell Tyler Roady Maryam Ghandali Nataliia Verovkina Wafik S. El-Deiry 7 Martin Taylor 6 and Stephanie L. Graff Laboratory of Translational Oncology Experimental Cancer Therapeutics, Warren Alpert Medical School, Brown University, RI 02903, USA Department Pathology Medicine, Joint Program in Biology, Lifespan Health System Legorreta Center at Pathobiology Graduate Program, on the Biology Aging, Hematology/Oncology Division, Correspondence to: Ryspayeva, email: [email protected] Keywords: breast cancer; oncogenic pathways; signal dysregulation therapeutic approaches; clinical trials Received: December 20, 2024 Accepted: March 03, 2025 Published: 13, Copyright: © et al. This is an open access article distributed under terms Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, reproduction any medium, provided original author source are credited. ABSTRACT provides a comprehensive analysis signaling pathways implicated cancer (BC), most prevalent malignancy among women leading cause cancer-related mortality globally. Special emphasis placed structural dynamics protein complexes that integral to regulation these cascades. Dysregulation cellular fundamental aspect BC pathophysiology, with both upstream downstream cascade activation contributing process aberrations not only drive tumor growth, but also contribute resistance against current treatments. The review explores alterations within across different subtypes highlights potential strategies targeting pathways. Additionally, influence specific mutations decision-making examined, underscoring their relevance particular subtypes. discusses approved modalities ongoing disrupted However, further investigation necessary fully elucidate underlying mechanisms optimize personalized treatment approaches.

Language: Английский

---